Abdou Y et al. Race and clinical outcomes in the RxPONDER trial (SWOG S1007). SABCS 2022;Abstract GS1-01.
Andre F et al. Biomarkers for adjuvant endocrine and chemotherapy in early-stage breast cancer: ASCO guideline update. J Clin Oncol 2022;40(16):1816-37. Abstract
Bardia A et al. Datopotamab deruxtecan (Dato-DXd) in advanced triple-negative breast cancer (TNBC): Updated results from the phase 1 TROPION-PanTumor01 study. SABCS 2022;Abstract P6-10-03.
Bardia A et al. EMERALD phase 3 trial of elacestrant versus standard of care endocrine therapy in patients with ER+/HER2- metastatic breast cancer: Updated results by duration of prior CDK4/6i in metastatic setting. SABCS 2022;Abstract GS3-01.
Bartsch R et al. Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: A single-arm, phase 2 trial. Nat Med 2022;28(9):1840-7. Abstract
Bidard F-C et al. Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: Results from the randomized Phase III EMERALD trial. J Clin Oncol 2022;40(28):3246-56. Abstract
Cortes J et al. Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer. N Engl J Med 2022;387(3):217-26. Abstract
Curigliano G et al. Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): Final overall survival analysis. Ann Oncol 2022;33(3):321-9. Abstract
Hurvitz SA et al. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: Updated survival results of the randomized, phase 3 study DESTINY-Breast03. SABCS 2022;Abstract GS2-02.
Hurvitz SA et al. TRIO-US B-12 TALENT: Neoadjuvant trastuzumab deruxtecan with or without anastrozole for HER2-low, HR+ early stage breast cancer. SABCS 2022;Abstract GS2-03.
Johnston S et al. Abemaciclib plus endocrine therapy for HR+, HER2-, node-positive, high-risk early breast cancer: Results from a pre-planned monarchE overall survival interim analysis, including 4-year efficacy outcomes. SABCS 2022;Abstract GS1-09.
Korde LA et al. Use of immune checkpoint inhibitor pembrolizumab in the treatment of high-risk, early-stage triple-negative breast cancer: ASCO guideline rapid recommendation update. J Clin Oncol 2022;40(15):1696-8. Abstract
Krop I et al. Trastuzumab deruxtecan vs physician’s choice in patients with HER2+ unresectable and/or metastatic breast cancer previously treated with trastuzumab emtansine: primary results of the randomized phase 3 study DESTINY-Breast02. SABCS 2022;Abstract GS2-01.
Krop IE at al. Results from the phase 1/2 study of patritumab deruxtecan, a HER3-directed antibody-drug conjugate (ADC), in patients with HER3-expressing metastatic breast cancer (MBC). ASCO 2022;Abstract 1002.
Lin NU et al. Intracranial efficacy and survival with tucatinib plus trastuzumab and capecitabine for previously treated HER2-positive breast cancer with brain metastases in the HER2CLIMB trial. J Clin Oncol 2020;38(23):2610-9. Abstract
Loibl S et al. Adjuvant pertuzumab and trastuzumab in patients with early HER-2 positive breast cancer in APHINITY: 8.4 years' follow-up. ESMO Virtual Plenary 2022;Abstract VP6-2022.
Nitz UA et al. Endocrine therapy response and 21-gene expression assay for therapy guidance in HR+/HER2- early breast cancer. J Clin Oncol 2022;40(23):2557-67. Abstract
Meric-Bernstam F et al. Phase 1 TROPION-PanTumor01 study evaluating datopotamab deruxtecan (dato-DXd) in unresectable or metastatic hormone receptor–positive/HER2–negative breast cancer (BC). SABCS 2022;Abstract PD13-08.
Modi S et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med 2022;387(1):9-20. Abstract
Oliveira M et al. Camizestrant, a next generation oral SERD vs fulvestrant in post-menopausal women with advanced ER-positive HER2-negative breast cancer: Results of the randomized, multi-dose Phase 2 SERENA-2 trial. SABCS 2022;Abstract GS3-02.
Perez-Garcia JM et al. Trastuzumab deruxtecan in patients with unstable central nervous system involvement from HER2-low advanced breast cancer: The DEBBRAH trial. SABCS 2022;Abstract PD7-02.
Pusztai L et al. Event-free survival by residual cancer burden after neoadjuvant pembrolizumab + chemotherapy versus placebo + chemotherapy for early TNBC: Exploratory analysis from KEYNOTE-522. ASCO 2022;Abstract 503.
Schmid P et al. Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Updated results from BEGONIA, a phase 1b/2 study. SABCS 2022;Abstract PD11-09.
Schmid P et al. Event-free survival with pembrolizumab in early triple-negative breast cancer. N Engl J Med 2022;386(6):556-67. Abstract
Stephen RDJ et al. Abemaciclib plus endocrine therapy for HR+, HER2-, node-positive, high-risk early breast cancer: Results from a pre-planned monarchE overall survival interim analysis, including 4-year efficacy outcomes. SABCS 2022;Abstract GS1-09.
Sparano J et al. Trial assigning individualized options for treatment (TAILORx): An update including 12-year event rates. SABCS 2022;Abstract GS1-05.
Ramakrishna N et al. Management of advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: ASCO guideline update. J Clin Oncol 2022;40(23):2636-55. Abstract
Rugo HS et al. Overall survival (OS) results from the phase III TROPiCS-02 study of sacituzumab govitecan (SG) vs treatment of physician's choice (TPC) in patients (pts) with HR+/HER2- metastatic breast cancer (mBC). ESMO 2022;Abstract LBA76.
Turner NC et al. Capivasertib and fulvestrant for patients with aromatase inhibitor-resistant hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: results from the Phase III CAPItello-291 trial. SABCS 2022;Abstract GS3-04.
Tutt ANJ et al. Pre-specified event driven analysis of overall survival (OS) in the OlympiA phase III trial of adjuvant olaparib (OL) in germline BRCA1/2 mutation (gBRCAm) associated breast cancer. ESMO Virtual Plenary 2022;Abstract VP1-2022.